| Title: | Multimorbidity and the risk of major adverse kidney events: findings from the UK Biobank cohort |
| Journal: | Clinical Kidney Journal |
| Published: | 11 Apr 2021 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/34754437/ |
| DOI: | https://doi.org/10.1093/ckj/sfab079 |
| URL: | https://academic.oup.com/ckj/article-pdf/14/11/2409/41100078/sfab079.pdf |
Publication 5429
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BACKGROUND: Multimorbidity [the presence of two or more long-term conditions (LTCs)] is associated with a heightened risk of mortality, but little is known about its relationship with the risk of kidney events.</p>
METHODS: Associations between multimorbidity and major adverse kidney events [MAKE: the need for long-term kidney replacement therapy, doubling of serum creatinine, fall of estimated glomerular filtration rate (eGFR) to <15 mL/min/1.73 m2 or 30% decline in eGFR] were studied in 68 505 participants from the UK Biobank cohort. Participants were enrolled in the study between 2006 and 2010. Associations between LTC counts and MAKE were tested using survival analyses accounting for the competing risk of death.</p>
RESULTS: Over a median follow-up period of 12.0 years, 2963 participants had MAKE. There were associations between LTC count categories and the risk of MAKE [one LTC adjusted subhazard ratio (sHR) = 1.29, 95% confidence interval (CI) 1.15-1.45; two LTCs sHR = 1.74 (95% CI 1.55-1.96); and three or more LTCs sHR = 2.41 (95% CI 2.14-2.71)]. This finding was more pronounced when only cardiometabolic LTCs were considered [one LTC sHR = 1.58 (95% CI 1.45-1.73); two LTCs sHR = 3.17 (95% CI 2.80-3.59); and three or more LTCs sHR = 5.24 (95% CI 4.34-6.33)]. Combinations of LTCs associated with MAKE were identified. Diabetes, hypertension and coronary heart disease featured most commonly in high-risk combinations.</p>
CONCLUSIONS: Multimorbidity, and in particular cardiometabolic multimorbidity, is a risk factor for MAKE. Future research should study groups of patients who are at high risk of progressive kidney disease based on the number and type of LTCs.</p>
14 Authors
- Michael K Sullivan
- Bhautesh Dinesh Jani
- Jennifer S Lees
- Claire E Welsh
- Alex McConnachie
- Bethany Stanley
- Paul Welsh
- Barbara I Nicholl
- Donald M Lyall
- Juan-Jesus Carrero
- Dorothea Nitsch
- Naveed Sattar
- Frances S Mair
- Patrick B Mark
Enabling scientific discoveries that improve human health